Fidelity Investments
PYXS icon

Fidelity Investments’s Pyxis Oncology PYXS Stock Holding History

Fidelity Investments’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.4K Sell
11,912
-946
-7% -$1.43K ﹤0.01% 4567
2025
Q4 		$14.8K Sell
12,858
-2,597
-17% -$9.16K ﹤0.01% 4594
2025
Q3 		$34.3K Sell
15,455
-79,391
-84% -$114K ﹤0.01% 4141
2025
Q2 		$104K Buy
94,846
+8,191
+9% +$9.23K ﹤0.01% 3594
2025
Q1 		$84.9K Buy
86,655
+1,767
+2% +$2.36K ﹤0.01% 3628
2024
Q4 		$132K Buy
84,888
+80,916
+2,037% +$233K ﹤0.01% 3429
2024
Q3 		$14.6K Buy
+3,972
New +$13.9K ﹤0.01% 4306
2024
Q2 		– Sell
-1
Closed -$4 – 5584
2024
Q1 		$4 Buy
+1
New +$4 ﹤0.01% 5310
2023
Q4 		– Sell
-346
Closed -$688 – 5608
2023
Q3 		$688 Buy
346
+175
+102% +$405 ﹤0.01% 4689
2023
Q2 		$438 Buy
+171
New +$542 ﹤0.01% 4829
2022
Q4 		– Sell
-855
Closed -$2K – 5537
2022
Q3 		$2K Sell
855
-3
-0.3% -$8 ﹤0.01% 4579
2022
Q2 		$2K Buy
858
+729
+565% +$1.94K ﹤0.01% 4586
2022
Q1 		$1K Buy
+129
New +$943 ﹤0.01% 4836

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments's PYXS Position: Q1 2026 in Review

Fidelity Investments reduced its Pyxis Oncology (PYXS) stake by 7.4% in Q1 2026, selling an estimated $1.43K and leaving 11,912 shares worth $17.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4567.

Fidelity Investments first reported a position in PYXS in Q1 2022 and has held it in 13 quarters since. The position peaked at $132K in Q4 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Fidelity Investments held 11,912 shares of Pyxis Oncology worth $17.4K as of Q1 2026.
  • Fidelity Investments sold 946 Pyxis Oncology shares in Q1 2026, an estimated $1.43K.
  • Pyxis Oncology made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4567 holding.
  • Fidelity Investments first reported a position in Pyxis Oncology in Q1 2022 and has held it in 13 quarters since.
  • Fidelity Investments's Pyxis Oncology position peaked at $132K in Q4 2024.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.